Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME of [14C]-MRM-3379 in Healthy Male Participants
NCT07712718Phase 1Completed
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- May 2026
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DNS-3379, sponsored by Mirum Pharmaceuticals, Inc. Primary endpoints: Total radioactivity recovery of MRM-3379 in urine and feces up to 11 days, Maximum observed concentration of MRM-3379 and 2 metabolites in plasma up to 11 days and 8 more. Started May 2026; status: completed.
02
Drugs
DNS-3379
Beyond the preview
Go deeper on NCT07712718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07712718.